epilepsy

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg Thalmann. The Analyst Analyst Michael Higgins initiated coverage of Marinus...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday's pre-market session but then sold off after the opening bell. The...

Zogenix, Inc. (NASDAQ: ZGNX) shares jumped another 5.6 percent Monday morning after exploding higher by 172 percent Sept. 29 in the wake of positive data on anti-epileptic drug ZX008. Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) plummeted 9.6 percent last Friday as well, and dropped another...

The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, the company’s market cap went up in smoke to the tune of a more than 50 percent...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported Tuesday its second-quarter results along with a series of updates concerning ongoing clinical trials and when investors can expect top-line data. Zynerba was expected to release phase 2 STAR 1 trial data of its ZYN002 for the treatment of adult...

Shares of Pfizer Inc. (NYSE: PFE) were little changed after the company said it will appeal a $106 million fine by the United Kingdom's competition regulator, the Competition and Markets Authority (CMA). According to The Wall Street Journal, Pfizer was slapped with a £84.2 million...

Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Even though company indicated there were certain sub-demographics of better responders in the greater...

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) is up more than 3 percent Thursday and more than 17 percent year-to-date. According to a press release, Supernus' most recent earnings release earlier in March came in as records for both the fourth quarter and the full year 2015. "2015 was...

Two bankers – both dead - each from a different cause. But, is there a common thread in the form of work-related stress? Moritz Erhardt, a summer intern with Bank of America (NYSE: BAC) in London was found unconscious in his apartment on Aug. 15. He was pronounced dead at the scene and police...